南方医科大学学报2023，Vol.43Issue(10)：1651-1656,6.DOI:10.12122/j.issn.1673-4254.2023.10.01
中性粒细胞/淋巴细胞、血小板/淋巴细胞比值是评价托法替尼治疗后类风湿关节炎活动性的有效指标
Neutrophil-lymphocyte and platelet-lymphocyte ratios for assessing disease activity in patients with rheumatoid arthritis receiving tofacitinib treatment
摘要
Abstract
Objective To evaluate the value of neutrophil-to-lymphocyte ratio(NLR)and platelet-to-lymphocyte ratio(PLR)for assessing disease activity in patients with rheumatoid arthritis(RA)treated with tofacitinib.Methods This retrospective study was conducted among 98 RA patients in active stage treated with tofacitinib in Third Xiangya Hospital and 100 healthy control subjects from the Health Management Center of the hospital from 2019 to 2021.We collected blood samples from all the participants for measurement of erythrocyte sedimentation rate(ESR),high-sensitivity C-reactive protein(hs-CRP),interleukin-6(IL-6)and other blood parameters 1 month before and 6 months after tofacitinib treatment.We further evaluated PLR and NLR before and after tofacitinib treatment in the RA patients,and analyzed their correlations with RA disease activity.Results PLR and NLR increased significantly in RA patients as compared with the healthy controls.In the RA patients,PLR and NLR were positively correlated with the levels of hs-CRP,ESR,IL-6,Disease Activity Score of 28 joints-ESR(DAS28-ESR),anti-cyclic citrullinated peptide(CCP),and rheumatoid factor(RF)before and after tofacitinib treatment.Tofacitinib treatment for 6 months significantly decreased hs-CRP,ESR,IL-6,CCP,RF and DAS28-ESR levels in the RA patients.Conclusion NLR and PLR can be useful biomarkers for assessing disease activity in RA patients treated with tofacitinib.关键词
中性粒细胞与淋巴细胞比值/血小板与淋巴细胞比值/类风湿关节炎/托法替尼Key words
neutrophil-lymphocyte ratio/platelet-lymphocyte ratio/rheumatoid arthritis/tofacitinib引用本文复制引用
唐娟,陈娟,林国新,张浩,桂明,李楠楠,谷依红,罗林娟,孙剑..中性粒细胞/淋巴细胞、血小板/淋巴细胞比值是评价托法替尼治疗后类风湿关节炎活动性的有效指标[J].南方医科大学学报,2023,43(10):1651-1656,6.基金项目
Supported by National Natural Science Foundation for Distinguished Young Scholars of China(81900634)and Natural Sciences Foundation of Hunan Province for Distinguished Young Scholars(2021JJ40947). 国家自然科学基金(81900634) （81900634）
湖南省自然科学基金(2021JJ40947) （2021JJ40947）
